Enhancing fungal and nematode resistance in legumes through phytoalexin accumulation via MtMYB8 transcription factor

Overview

This research proposes a plant biotechnology strategy to improve fungal and nematode resistance in legume crops by engineering constitutive accumulation of phytoalexins, which are natural secondary metabolites with anti-microbial, anti-fungal, and anti-nematode properties. The approach centers on over-expressing a novel transcription factor, MtMYB8, originally discovered in Medicago, to drive elevated production of isoflavonoid-derived phytoalexins in soybean and alfalfa. In soybean, the target phytoalexin is glyceollin, a compound with demonstrated anti-fungal and anti-nematode activity. By shifting phytoalexin biosynthesis from an inducible response to a constitutive state, engineered plants could gain durable, broad-spectrum protection against pathogens that currently reduce legume yields.

Technical specifications

• Core discovery: MtMYB8, a novel MYB transcription factor, induces massive accumulation of medicarpin in Medicago hairy roots
• Target crops: Soybean (producing glyceollin) and alfalfa, both amenable to existing laboratory transformation protocols
• Metabolic pathway: Isoflavonoid biosynthesis, redirected toward constitutive phytoalexin production rather than infection-induced accumulation
• Analytical validation: LC/MS profiling to quantify phytoalexin levels in transgenic tissues, supported by state-of-the-art mass spectrometry infrastructure
• Bioassay pipeline: Greenhouse-based anti-fungal and anti-nematode challenge assays on three selected high-phytoalexin transgenic lines
• Scale of development: Approximately 30 independent transgenic lines per crop species for robust statistical evaluation

Technology readiness level

The technology is currently at an early-to-mid stage of development. Proof-of-concept has been established in Medicago hairy roots, where MtMYB8 over-expression successfully drives massive medicarpin accumulation. The next critical milestones are generating stable transgenic soybean and alfalfa lines, confirming elevated phytoalexin levels by LC/MS, and validating pathogen resistance in greenhouse trials. The research team brings deep expertise in isoflavonoid biosynthesis and bioengineering, along with established transformation capabilities for both target crops. Upon successful greenhouse validation, the pathway toward field trials and potential commercial deployment in legume disease management would open.